aibio
Listings ·
Xencor holders approve 4,000,000-share increase to 2023 equity plan
The annual meeting on June 16, 2026 also elected nine directors and ratified KPMG LLP as auditor.
XNCR Xencor, Inc.
Xencor (XNCR) news
Latest Xencor news
- Distress
Genentech to end Xencor collaboration and license agreement September 4, 2026
Genentech elected to terminate the agreement for convenience. Xencor says it expected the move.
- Distress
Xencor says 2023 and 2024 interim financials can't be relied on, will restate royalty as debt
Xencor's audit committee concluded that a 2023 royalty deal with OMERS Life Sciences should be debt, not deferred income, and the company says its 2023 operating cash flow was overstated by $163.0 million. It also found tax misstatements. The company says cash and marketable debt securities are not affected.
Xencor annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $125.6 million | $110.5 million |
| Research and development | $239.4 million | $227.7 million |
| Net income (loss) | -$91.9 million | -$232.6 million |
| Cash from operations | -$135.1 million | -$202.2 million |
| Cash and equivalents | $54.1 million | $40.9 million |
Questions about Xencor
What is the ticker symbol of Xencor?
Xencor, Inc. trades under the ticker XNCR on NASDAQ.
Where is Xencor listed?
Xencor, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:XE9; LS:A1W96L; LSX:A1W96L.
What is the SEC CIK of Xencor?
The SEC Central Index Key (CIK) for Xencor, Inc. is 1326732. Its filings are on SEC EDGAR.
How many shares does Xencor have outstanding?
74,353,397 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.
Which country or territory is Xencor listed under?
Our directory records Xencor, Inc. under United States.
What does Xencor do?
Our directory classifies Xencor, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Xencor?
The ISIN recorded for Xencor, Inc. is US98401F1057.
Does aibio.space cover Xencor?
aibio.space lists Xencor, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Xencor incorporated?
SEC records list its state or country of incorporation as DE.
What was Xencor's revenue last year?
$125.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Xencor profitable?
Xencor, Inc. reported a net loss of $91.9 million for the fiscal year ended Dec 31, 2025, and used $135.1 million of cash in operations, per its annual report to the SEC.
How much does Xencor spend on research and development?
$239.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Xencor have?
$44.7 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Xencor (XNCR) stock news?
Our latest story on Xencor, dated Jun 18, 2026: "Xencor holders approve 4,000,000-share increase to 2023 equity plan". The annual meeting on June 16, 2026 also elected nine directors and ratified KPMG LLP as auditor. Source.
Is Xencor in financial distress?
Our latest distress story, dated Mar 9, 2026: "Genentech to end Xencor collaboration and license agreement September 4, 2026". Genentech elected to terminate the agreement for convenience. Xencor says it expected the move. Source.
Investor discussion: Xencor
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01). Source
- Legal
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Xencor Inc
- CIK
- 1326732
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- XNCR (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Accelerated filer
- Business address
- 465 N. HALSTEAD ST., PASADENA, CA, 91107
- Phone
- 626-305-5900
- Shares outstanding
- 74,353,397 as of 2026-07-31 (10-Q filed 2026-08-05)
Recent filings
Listing details
- Company
- Xencor, Inc.
- Ticker
- XNCR
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US98401F1057
- Other listed symbols
- GETTEX:XE9; LS:A1W96L; LSX:A1W96L
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction